Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinica...Show More
products_or_servicesInnovative eye care treatments including OCS-01 (for diabetic macular edema and post-cataract surgery inflammation), OCS-02 (for dry eye disease and non-infectious anterior uveitis), and OCS-05 (for acute optic neuritis and other neuro-ophthalmic disorders).